Search Results
Jun 08, 2026, 03:29 ET LG Teams with NVIDIA to Shape the Future with M.A.P. (Mobility / AI Infra / Physical AI)
technologies, and will develop high-performance sensing modules and optical components optimized for NVIDIA AI infrastructure.Furthermore, LG CNS is building an ecosystem that enables anyone to easily adopt AI robots in manufacturing and logistics sites. By integrating NVIDIA's robotics technologies,
More news about: LG
Jun 07, 2026, 21:00 ET バイブコーディングの先へ：エージェント型AIが挑む大規模システム開発
https://www.prnewswire.com/jp/news-releases/ai-302791149.htmlSOURCE LG CNS
More news about: LG CNS
Jun 05, 2026, 20:30 ET Ractigen Therapeutics Announces ADA 2026 Late-Breaking Presentation Highlighting saRNA as a New Frontier in Obesity Control
development of RNA-based solutions, including siRNAs, where applicable, to target life-threatening, fast-progressing conditions such as those in the CNS. Committed to scientific excellence and patient-centered innovation, Ractigen strives to transform healthcare through the power of RNA therapeutics.
More news about: Ractigen Therapeutics
Jun 04, 2026, 16:03 ET B. Riley Securities to Host Mind, Muscle & Vision Healthcare Summit on July 16, 2026
Vision Summit comes at a highly dynamic time for this fast-growing sub-sector. Year-to-date in 2026, pharma strategics have committed over $30 billion to CNS, muscle, and ophthalmology programs - roughly 25% of total deal activity by size and volume. These exits represent a durable, accelerating trend that
More news about: B. Riley Securities
Jun 04, 2026, 07:45 ET Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia
combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death.Because of the risks of CNS depression and abuse and
More news about: Jazz Pharmaceuticals plc
Jun 03, 2026, 08:00 ET CRC CEO Tom Zoda, Ph.D., Chairs ASCP 2026 Panel on Preventable Failure Risk in CNS Clinical Trials
operational alignment, and the cumulative operational and methodological pressures that can complicate interpretation in CNS studies.Throughout the discussion, panelists emphasized that many CNS trial failures are not attributable to a single operational issue, but rather to cumulative factors that can increase
More news about: Cognitive Research Corporation
Jun 03, 2026, 08:00 ET IDefine and UT Southwestern Announce Research Collaboration to Advance Gene Therapy for Rare Disease Kleefstra Syndrome
feasibility and safety of EHMT1 gene replacement therapy using next-generation gene delivery technology designed to target the central nervous system (CNS)."This landmark research collaboration represents a meaningful step forward in our mission to accelerate research that can lead to a first treatment
More news about: IDefine - The Kleefstra Syndrome Foundation
Jun 03, 2026, 08:00 ET Lundbeck Partners with Cradle to Discover and Optimize Brain Disorder Treatments
Collaboration's initial focus will focus on two antibody programs targeting CNS diseases VALBY, Denmark and AMSTERDAM, June 3, 2026 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck), a global biopharmaceutical company
More news about: Cradle
Jun 03, 2026, 08:00 ET Lundbeck Partners with Cradle to Discover and Optimize Brain Disorder Treatments
Collaboration's initial focus will focus on two antibody programs targeting CNS diseases VALBY, Denmark and AMSTERDAM, June 3, 2026 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck), a global biopharmaceutical
More news about: Cradle
Jun 03, 2026, 00:04 ET Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study
2004.c. LLDAS definition: (1) SLE Disease Activity Index (SLEDAI)-2K ≤4, with no activity in major organ systems (renal, central nervous system (CNS), cardiopulmonary, vasculitis, fever) and no hemolytic anemia or gastrointestinal activity; (2) no new lupus disease activity compared with the previous
More news about: Johnson & Johnson
Jun 03, 2026, 00:03 ET Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
activity across 11 organ system domains [cutaneous, pulmonary, renal, articular, muscular, peripheral nervous system (PNS), central nervous system (CNS), hematological, glandular, constitutional, lymphadenopathy and lymphoma; a higher score indicates greater symptom severity.ABOUT
More news about: Johnson & Johnson
Jun 02, 2026, 11:15 ET Injectable Drug Delivery Market Size to Grow from US$655.1 Billion in 2026 to US$1182.2 Billion by 2033 | Persistence Market Research
In-Situ Forming Gels, Nanoparticle-Based Systems), Route of Administration (Injectable, Implant, Oral), Therapeutic Area (Cancer, Central Nervous System (CNS) Disorders, Hormone Disorders, Infectious Diseases, Pain Management, Contraception), Material Used (Polymer, Non-Polymer), Distribution Channel (Hospital
More news about: Persistence Market Research Pvt. Ltd.
Jun 01, 2026, 13:02 ET Perceptive Discovery and Certis Oncology Announce Strategic Collaboration to Advance Radiopharmaceutical Development
decisions.About Perceptive DiscoveryPerceptive Discovery is a leading preclinical and translational research organization supporting oncology, CNS, and radiopharmaceutical development from discovery through early clinical translation. Through integrated expertise in radiochemistry, multimodal imaging,
More news about: Perceptive Discovery
Jun 01, 2026, 08:31 ET The Evolving EGFR NSCLC Market: 8 Emerging Late-stage Therapies to Watch | DelveInsight
targeted therapy with the potential to enhance the treatment landscape for EGFR-mutant NSCLC, especially in patients with rare EGFR alterations and CNS involvement, according to Aparna Thakur, Assistant Project Manager, Forecasting at DelveInsight. Should ongoing global studies continue to deliver encouraging
More news about: DelveInsight Business Research, LLP
May 31, 2026, 20:00 ET D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC
cycling and suppressing oncogenic signaling. Preclinical studies show robust potency, complete KRAS G12C engagement at clinically relevant exposures, and CNS penetration capability. Elisrasib is currently being evaluated globally in a Phase 2 monotherapy and combination trial across KRAS G12C–mutant solid
More news about: D3 Bio
May 31, 2026, 17:36 ET Servier to Present Extended Follow-Up Results from the Phase 3 INDIGO Trial Showing Durable and Sustained Treatment Benefits of VORANIGO® (vorasidenib) at ASCO 2026
sub-divided into only three categories:Astrocytoma, IDH-mutant (CNS WHO grades 2-4)Oligodendroglioma, IDH-mutant and1p19q-codeleted (CNS WHO grades 2-3)Glioblastoma, IDH-wildtype (CNS WHO grade 4)VORANIGO IMPORTANT SAFETY INFORMATIONWhat
More news about: Servier Pharmaceuticals
May 31, 2026, 08:01 ET Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
overall survival (OS), EFS as assessed by blinded independent central review (BICR), time to distant disease recurrence in the central nervous system (CNS) as assessed by investigator and BICR, progression-free survival on the next line of treatment (PFS2), positive predictive value (PPV) of RET
More news about: Eli Lilly and Company
May 30, 2026, 20:09 ET Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026
CEO of Dizal, said: "Main reasons for patients relapsed from 3rd generation EGFR TKI treatment include acquired resistance mutations and CNS metastasis. DZD6008 was designed to address these clinical issues. The data presented confirmed that DZD6008 met our design criteria and has the potential
More news about: Dizal Pharmaceutical
May 30, 2026, 14:30 ET Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
Illinois.SEZ6 is a cell surface transmembrane protein involved in neuronal development that is primarily expressed in central nervous system (CNS) tissues. A large-scale RNA analysis demonstrated that SEZ6 is highly expressed across SCLC and other tumors of neuroendocrine origin. In SCLC, expression
More news about: Whitehawk Therapeutics, Inc.
May 30, 2026, 08:05 ET ROADS Phase 3 Clinical Trial Data Presented at ASCO26 Show GammaTile® Provides Superior Tumor Control Leading to Patients Living Longer Without Recurrence Compared to Standard of Care in Newly Diagnosed Operable Brain Metastases
data?The multicenter ROADS trial was co-led by Jeffrey Weinberg, MD, professor of Neurosurgery, and Thomas H. Beckham, MD, PhD, assistant professor of CNS Radiation Oncology at The University of Texas MD Anderson Cancer Center."Surgery is the primary treatment for operable brain metastases, but tumor
More news about: GT Medical Technologies
May 29, 2026, 23:29 ET Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
RET fusion-positive NSCLC, regardless of line of therapy, in a largely poor-prognostic patient population. Favorable CNS efficacy was observed in patients with measurable baseline CNS metastases. The safety profile was manageable, with no unexpected safety signals.Professor Qing Zhou, principal
More news about: Kelun-Biotech
May 29, 2026, 07:00 ET Alaw Therapeutics Announces Two Major Pipeline Milestones Advancing Brain-Penetrant CDK Oncology Programs
CDK-directed oncology," said Idean Marvasty, President and CFO of Alaw. "The inability to achieve meaningful CNS exposure has remained a fundamental limitation, leaving patients with brain metastases and primary CNS tumors underserved by targeted cell-cycle therapies. AL-605 and AL-433 were specifically engineered
More news about: Alaw Therapeutics
May 28, 2026, 13:15 ET Braeburn Presents New Data at 2026 ASCP Annual Meeting Demonstrating Opioid Withdrawal Suppression at Low Buprenorphine Plasma Concentrations
emergency medical help, even if an agent is administered.Concomitant Use of Benzodiazepines or other CNS Depressants: Concomitant use of buprenorphine and benzodiazepines or other CNS depressants (e.g., alcohol, non-benzodiazepine sedative/hypnotics, anxiolytics, tranquilizers, muscle relaxants,
More news about: Braeburn
May 28, 2026, 11:32 ET NeuLogiq® Platform Helps Confirm No Evidence of Psychotomimetic, Hallucinatory, or Dissociative Effects in a Phase 1b Study of a Novel Neuroplastogen Developed for Major Depressive Disorder
neuropsychiatry" said Brian Murphy, PhD, Founder and Chief Scientific Officer of Cumulus. "Over time, NeuLogiq has evolved to be used across the spectrum of CNS conditions including multiple psychiatric disorders. The data presented today along with the data presented by Delix at ASCP 2025 confirms that the NeuLogiq
More news about: Cumulus Neuroscience
May 28, 2026, 10:41 ET The Multiple Sclerosis Association of America (MSAA) Expands National Reach of Research Initiative to More than 1,000 Participants Across 20 Locations
Sclerosis Multiple sclerosis (MS) is a disease of the central nervous system (CNS), which consists of the brain, optic nerves, and spinal cord. MS damages or destroys the protective covering (known as myelin) surrounding the nerves of the CNS and can potentially injure the nerves as well. This damage causes reduced
More news about: Multiple Sclerosis Association of America